Go Pro

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$258.48
-1.9%
$236.47
$154.80
$269.43
$634.06B0.248.30 million shs6.38 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$19.14
-0.8%
$18.02
$14.02
$22.87
$37.04B0.4718.72 million shs14.45 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$137.64
-1.7%
$109.46
$50.49
$141.10
$9.01B1.79823,845 shs1.17 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.91%-1.54%+9.12%+8.45%+65.62%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.73%-3.39%+6.87%+10.19%-7.69%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-1.73%+4.57%+30.01%+39.28%+163.22%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$258.48
-1.9%
$236.47
$154.80
$269.43
$634.06B0.248.30 million shs6.38 million shs
Kenvue Inc. stock logo
KVUE
Kenvue
$19.14
-0.8%
$18.02
$14.02
$22.87
$37.04B0.4718.72 million shs14.45 million shs
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$137.64
-1.7%
$109.46
$50.49
$141.10
$9.01B1.79823,845 shs1.17 million shs
The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
-1.91%-1.54%+9.12%+8.45%+65.62%
Kenvue Inc. stock logo
KVUE
Kenvue
-0.73%-3.39%+6.87%+10.19%-7.69%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-1.73%+4.57%+30.01%+39.28%+163.22%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
2.74
Moderate Buy$257.74-0.29% Downside
Kenvue Inc. stock logo
KVUE
Kenvue
2.19
Hold$19.331.04% Upside
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2.88
Moderate Buy$116.93-15.05% Downside

Current Analyst Ratings Breakdown

Latest JNJ, PTGX, and KVUE Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/8/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price TargetOverweight$283.00 ➝ $284.00
7/8/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price TargetBuy$285.00 ➝ $298.00
7/7/2026
Kenvue Inc. stock logo
KVUE
Kenvue
DowngradeStrong-BuyHold
7/7/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Boost Price TargetBuy$121.00 ➝ $145.00
7/6/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Set Price TargetBuy$290.00
7/1/2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
Reiterated RatingBuy
6/26/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Set Price Target$270.00
6/26/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
Boost Price TargetBuy$266.00 ➝ $270.00
6/15/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
DowngradeBuy (B)Buy (B-)
6/15/2026
Kenvue Inc. stock logo
KVUE
Kenvue
UpgradeHold (C-)Hold (C)
5/29/2026
Kenvue Inc. stock logo
KVUE
Kenvue
DowngradeHold (C)Hold (C-)
(Data available from 7/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$94.19B6.61$13.85 per share18.66$33.85 per share7.64
Kenvue Inc. stock logo
KVUE
Kenvue
$15.12B2.43$1.37 per share13.99$5.62 per share3.40
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$46.02M192.34N/AN/A$9.83 per share14.00
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$26.80B$8.6529.8820.482.5821.83%32.60%13.29%7/15/2026 (Estimated)
Kenvue Inc. stock logo
KVUE
Kenvue
$1.47B$0.8522.5115.561.4610.61%20.81%8.21%8/6/2026 (Estimated)
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$130.15M-$1.81N/AN/AN/A-154.88%-17.76%-16.47%8/5/2026 (Estimated)

Latest JNJ, PTGX, and KVUE Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/6/2026Q2 2026
Kenvue Inc. stock logo
KVUE
Kenvue
$0.32N/AN/AN/A$3.97 billionN/A
8/5/2026Q2 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
$2.11N/AN/AN/A$190.30 millionN/A
7/15/2026Q2 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.84N/AN/AN/A$25.02 billionN/A
5/7/2026Q1 2026
Kenvue Inc. stock logo
KVUE
Kenvue
$0.27$0.32+$0.05$0.25$3.84 billion$3.91 billion
5/5/2026Q1 2026
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
-$0.5004$0.05+$0.5504$0.05$11.70 million$56.37 million
4/14/2026Q1 2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$2.68$2.70+$0.02$2.14$23.60 billion$24.06 billion
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
$5.362.07%+5.25%61.97%64 Years
Kenvue Inc. stock logo
KVUE
Kenvue
$0.834.34%N/A97.65%1 Years
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/AN/AN/AN/AN/A

Latest JNJ, PTGX, and KVUE Dividends

AnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
4/14/2026
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
quarterly$1.342.33%5/26/20265/26/20266/9/2026
4/29/2026
Kenvue Inc. stock logo
KVUE
Kenvue
quarterly$0.20754.82%5/13/20265/13/20265/27/2026
(Data available from 1/1/2013 forward)
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.46
1.03
0.77
Kenvue Inc. stock logo
KVUE
Kenvue
0.67
0.98
0.70
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
N/A
17.76
17.76

Institutional Ownership

CompanyInstitutional Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
69.55%
Kenvue Inc. stock logo
KVUE
Kenvue
97.64%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
98.63%

Insider Ownership

CompanyInsider Ownership
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
0.16%
Kenvue Inc. stock logo
KVUE
Kenvue
1.59%
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
5.19%
CompanyEmployeesShares OutstandingFree FloatOptionable
Johnson & Johnson stock logo
JNJ
Johnson & Johnson
138,2002.41 billion2.40 billionOptionable
Kenvue Inc. stock logo
KVUE
Kenvue
22,0001.92 billion1.89 billionOptionable
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
12064.31 million60.97 millionOptionable

Recent News About These Companies

New Strong Buy Stocks for July 9th

New MarketBeat Followers Over Time

Media Sentiment Over Time

Johnson & Johnson stock logo

Johnson & Johnson NYSE:JNJ

$258.48 -4.92 (-1.87%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$259.00 +0.52 (+0.20%)
As of 07/9/2026 08:00 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Kenvue stock logo

Kenvue NYSE:KVUE

$19.14 -0.16 (-0.80%)
Closing price 07/9/2026 03:59 PM Eastern
Extended Trading
$19.10 -0.03 (-0.16%)
As of 07/9/2026 07:51 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kenvue Inc. operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands. The Skin Health and Beauty segment provides face and body care, hair, sun, and other care products under the Neutrogena, Aveeno, Dr.Ci:Labo, Le Petit Marseillais, Lubriderm, Rogaine, and OGX brand names. The Essential Health segment offers oral and baby, women's health, wound, and other care products under the Listerine, Johnson's, Band-Aid, and Stayfree, o.b., tampons, Carefree, and Desitin Diaper Rash brands. The company was incorporated in 2022 and is headquartered in Skillman, New Jersey.

Protagonist Therapeutics stock logo

Protagonist Therapeutics NASDAQ:PTGX

$137.64 -2.43 (-1.73%)
Closing price 07/9/2026 04:00 PM Eastern
Extended Trading
$137.90 +0.27 (+0.19%)
As of 07/9/2026 05:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Protagonist Therapeutics, Inc., a biopharmaceutical company, develops peptide-based drugs for hematology and blood disorders, and inflammatory and immunomodulatory diseases. It is developing Rusfertide (PTG-300), an injectable hepcidin mimetic that completed phase 2 clinical trials for the treatment of polycythemia vera and other blood disorders; and JNJ-2113, an orally delivered investigational drug to block biological pathways that completed phase 2b clinical trials for the treatment of moderate-to-severe plaque psoriasis; and PN-943, an orally delivered, gut-restricted alpha 4 beta 7 specific integrin antagonist completed a phase 2 clinical trials in patients with moderate to severe ulcerative colitis. The company has a license and collaboration agreement with Takeda to commercialize rusfertide; and JNJ Innovative Medicines to co-develop Interleukin-23 receptor antagonist compound JNJ-2113. Protagonist Therapeutics, Inc. was incorporated in 2006 and is headquartered in Newark, California.